Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Itraconazole

FDA-approved product (capsule, oral), marketed as Itraconazole, Onmel, Sporanox and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Itraconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Blastomycosis
  • Candidiasis
  • Fungal infectious disease
  • Lung disease
  • Tinea
  • Tinea unguium

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC02; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Itraconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Itraconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Drug-Drug Interaction Study of Vorolanib Tablets in Healthy Participants

    NCT07809789 · start 2026-09

    Registered record
    Registry ID
    NCT07809789
    Conditions
    DDI (Drug-Drug Interaction)
    Interventions
    vorolanib and rifampicin; vorolanib and itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-09
    Completion
    2027-03
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDDI (Drug-Drug Interaction)
    Interventionvorolanib and rifampicin; vorolanib and itraconazole
    PhasePhase 1
    Registry statusRecruiting

  • A Trial of Lu AH69593 in Healthy Participants

    NCT07775261 · start 2026-08-27

    Registered record
    Registry ID
    NCT07775261
    Conditions
    Healthy Participants
    Interventions
    Lu AH69593; Itraconazole; Carbamazepine; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-08-27
    Completion
    2026-11-06
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionLu AH69593; Itraconazole; Carbamazepine; Midazolam
    PhasePhase 1
    Registry statusNot yet recruiting

  • Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

    NCT07620041 · start 2026-06-09

    Registered record
    Registry ID
    NCT07620041
    Conditions
    Refractory or Relapsed Solid Tumors
    Interventions
    QLC5508 (Investigational Product / Formulation T); QLC5508 (Reference Product / Formulation R); Itraconazole; Darolutamide; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-06-09
    Completion
    2027-02-05
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory or Relapsed Solid Tumors
    InterventionQLC5508 (Investigational Product / Formulation T); QLC5508 (Reference Product / Formulation R); Itraconazole; Darolutamide +1 more
    PhasePhase 1
    Registry statusRecruiting

  • A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)

    NCT07548606 · start 2026-05-11

    Registered record
    Registry ID
    NCT07548606
    Conditions
    Healthy
    Interventions
    Opevesostat; Prednisone; Fludrocortisone acetate; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2026-05-11
    Completion
    2026-06-18
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOpevesostat; Prednisone; Fludrocortisone acetate; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)

    NCT07335419 · start 2026-01-02

    Registered record
    Registry ID
    NCT07335419
    Conditions
    Healthy Adult Participants
    Interventions
    PF-07248144; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2026-01-02
    Completion
    2026-03-21
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adult Participants
    InterventionPF-07248144; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a Hopeful Avenue for Enhancing Treatment Options?

    NCT07069933 · start 2025-07

    Registered record
    Registry ID
    NCT07069933
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Standard care +itraconazole 200mg; Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-07
    Completion
    2025-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionStandard care +itraconazole 200mg; Chemotherapy
    PhasePhase 2
    Registry statusNot yet recruiting

  • Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of Carbamazepine or Itraconazole With Radiprodil in Healthy Adults

    NCT06965881 · start 2025-05-08

    Registered record
    Registry ID
    NCT06965881
    Conditions
    Tuberous Sclerosis Complex (TSC); Focal Cortical Dysplasia; Other Neurological Disorders
    Interventions
    Radiprodil with Carbamazepine; Radiprodil with Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2025-05-08
    Completion
    2025-07-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberous Sclerosis Complex (TSC); Focal Cortical Dysplasia; Other Neurological Disorders
    InterventionRadiprodil with Carbamazepine; Radiprodil with Itraconazole
    PhasePhase 1
    Registry statusTerminated

  • The Study on Effects of CYP3A and P-glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampin of HMPL-453 Tartrate Tablets

    NCT07697157 · start 2025-03-01

    Registered record
    Registry ID
    NCT07697157
    Conditions
    Health, Subjective
    Interventions
    HMPL-453 with Itraconazole; HMPL-453 with Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-03-01
    Completion
    2025-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealth, Subjective
    InterventionHMPL-453 with Itraconazole; HMPL-453 with Rifampin
    PhasePhase 1
    Registry statusCompleted

  • Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants

    NCT06495944 · start 2024-05-31

    Registered record
    Registry ID
    NCT06495944
    Conditions
    Healthy Adults
    Interventions
    Dazucorilant; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-05-31
    Completion
    2024-08-02
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adults
    InterventionDazucorilant; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

    NCT06400472 · start 2024-05-20

    Registered record
    Registry ID
    NCT06400472
    Conditions
    Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Triple Negative Breast Neoplasms; Pancreatic Neoplasm; Colorectal Neoplasms
    Interventions
    Sofe-M; bevacizumab; carboplatin; Itraconazole; pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-05-20
    Completion
    2029-06
    Enrolment
    575

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung +3 more
    InterventionSofe-M; bevacizumab; carboplatin; Itraconazole +1 more
    PhasePhase 1
    Registry statusRecruiting

  • Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects

    NCT06379958 · start 2024-04-08

    Registered record
    Registry ID
    NCT06379958
    Conditions
    Pharmacokinetics
    Interventions
    leramistat 40mg; Itraconazole 200 mg; Phenytoin 100 Mg Oral Capsule; Simvastatin 40mg; Upadacitinib 15 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2024-04-08
    Completion
    2024-09-30
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics
    Interventionleramistat 40mg; Itraconazole 200 mg; Phenytoin 100 Mg Oral Capsule; Simvastatin 40mg +1 more
    PhasePhase 1
    Registry statusUnknown

  • Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects

    NCT06232109 · start 2024-02-22

    Registered record
    Registry ID
    NCT06232109
    Conditions
    Drug Drug Interaction
    Interventions
    Fluvoxamine; Itraconazole; Paroxetine; ASN51
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-02-22
    Completion
    2024-07-03
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Drug Interaction
    InterventionFluvoxamine; Itraconazole; Paroxetine; ASN51
    PhasePhase 1
    Registry statusCompleted

  • A Study in Healthy Men to Test Whether Itraconazole Influences the Amount of BI 1584862 in the Blood

    NCT06041438 · start 2023-09-29

    Registered record
    Registry ID
    NCT06041438
    Conditions
    Healthy
    Interventions
    BI 1584862; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-09-29
    Completion
    2023-11-10
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBI 1584862; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558

    NCT05840952 · start 2023-07-04

    Registered record
    Registry ID
    NCT05840952
    Conditions
    COVID-19
    Interventions
    ALG-097558; Placebo; Midazolam; Itraconazole; Carbamazepine; ALG-097558 in solution formulation; ALG-097558 in tablet formulation
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-07-04
    Completion
    2024-04-29
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionALG-097558; Placebo; Midazolam; Itraconazole +3 more
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553

    NCT06105255 · start 2023-05-24

    Registered record
    Registry ID
    NCT06105255
    Conditions
    Healthy Male
    Interventions
    D-1553
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-05-24
    Completion
    2024-02-02
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Male
    InterventionD-1553
    PhasePhase 1
    Registry statusCompleted